Clinical Trial AI for Contract Research Organizations
A Phase III oncology trial costs between $20 million and $50 million on average. The single largest line item is patient recruitment. The single highest failure mode is enrollment timelines slipping by 6, 9, even 18 months — and each month of slippage costs the sponsor between $600,000 and $8 million in lost patent life. Contract research organizations live or die by how quickly they can identify, qualify, and enroll the right patients into the right protocols. That problem has become an AI problem.
This page is for CRO operations leaders, biostatistics teams, and clinical-data managers who are tired of explaining why eligibility screening is still done by humans reading PDFs in 2026. It is also for sponsors who buy CRO services and want to know what to ask for. If your work is therapeutic-area-specific oncology AI, see our oncology AI page — this page covers the operations layer that sits above any single therapeutic area.
Tell Us Your Requirements
Our experts are ready to understand your business goals.
Trusted by Industry Leaders Worldwide
Industries and Buyer Profiles We Have Delivered Against
Awards & Recognitions
Where CRO Economics Are Most Vulnerable
Contract research is a thin-margin business — 10–15% operating margin is healthy, and a single botched trial can erase a quarter’s profit. AI in CRO operations only matters if it touches one of the five places where the margin actually leaks.
Patient identification and qualification. Manual chart review against complex eligibility criteria is the dominant time sink in trial startup. AI that screens EHR populations against a protocol’s inclusion/exclusion logic — and ranks likely matches by confidence — collapses 8 weeks of work into 8 days.
Site selection and feasibility. The wrong site mix is a budget killer. AI over historical site performance data, local patient demographics, and competitive trial density gives operations a defensible site list before the protocol is finalized.
Source data verification. SDV is the labor backbone of clinical data management. Risk-based monitoring with AI-flagged anomaly detection in eCRFs cuts monitor hours significantly without sacrificing data quality.
Adverse event detection and pharmacovigilance. AI over case narratives and verbatim terms accelerates MedDRA coding and flags signals earlier in safety surveillance.
Real-world evidence pipelines. Sponsors increasingly buy RWE packages alongside trial services. CROs that can produce defensible OMOP-CDM datasets at speed are winning the work.
The Specific AI Capabilities CROs Are Asking For
In the past 18 months, the CRO buyer conversation has narrowed. These are the capabilities that win RFPs in 2026:
Eligibility screening against EHR populations. LLM reads inclusion/exclusion criteria, runs against FHIR resource queries (Condition, MedicationStatement, Observation, Procedure), produces a ranked list of likely-eligible patients with rationale citing the chart evidence. Confidence thresholds tunable per criterion. Audit trail per match.
Synthetic control arm generation. For rare disease and oncology trials where placebo arms are ethically constrained, AI generates synthetic control cohorts from RWE datasets using propensity matching against the actual enrolled population.
eCRF data quality and edit checks. Beyond rule-based checks: AI flags clinically improbable values, inconsistent narrative-vs-coded fields, and missing-data patterns that suggest site protocol drift.
MedDRA and WHODrug coding assistance. AI drafts MedDRA preferred terms from verbatim AE descriptions, with coder review. Same approach for concomitant medication WHODrug coding.
Protocol amendment impact analysis. When a protocol amendment is drafted, AI analyzes downstream impact on already-enrolled patients, eCRFs, statistical analysis plan, and site procedures. Useful for sponsor amendment-cost forecasting.
Decentralized trial patient-app intelligence. Drug adherence, symptom diary completion, ePRO submission cadence — AI flags participants drifting toward non-compliance before they hit the protocol violation threshold.
Where the Data Actually Lives
A CRO AI engagement is mostly a data-engineering engagement with a thin AI layer on top. The hard part is not the model. The hard part is reconciling EHR data across sponsor-site combinations.
OMOP CDM v5.4 is the dominant target schema for cross-site research workloads. Most of our CRO engagements build or extend an OMOP warehouse before any model training happens. See our hire clinical data engineers page for the data-engineering side.
FHIR R4 Bulk Data Access is the modern feeder for site-level patient identification. Where Bulk Data is not available, we fall back to HL7 v2 capture via Mirth Connect integration or direct SQL extraction from clinical data warehouses.
De-identification under HIPAA Safe Harbor and Expert Determination paths is non-negotiable. We build the de-id layer first, then everything else.
ClinicalTrials.gov and AACT are the canonical sources for competitive trial intelligence and protocol metadata.
MedDRA, WHODrug, SNOMED CT, LOINC, RxNorm, ICD-10-CM are the terminology backbone for any clinical reasoning the AI does.
For data-engineering background, read our coverage of healthcare data lake architecture.
How We Engage With CROs
Discovery Sprint — $45K, 4 weeks. Defines the AI use case (eligibility screening, RWE pipeline, AE coding assistance, etc.), maps it to the available data sources, identifies regulatory implications (21 CFR Part 11 for any system supporting regulated workflows), and produces an architecture document plus fixed-price quote for build. See the Discovery Sprint page.
MVP Sprint — $95K, 8 weeks. End-to-end build of the first use case on a representative dataset. Validated against held-out historical trial data where possible. Eval harness skeleton. See the MVP Sprint page.
Pilot-Ready Sprint — $145K, 12 weeks. Hardening for live trial use. 21 CFR Part 11 validation, audit logging, role-based access, documented system validation package. See the Pilot-Ready Sprint page.
Multi-trial platforming engagements. When the CRO wants the AI capability to span multiple sponsor trials, we use multi-engineer pods at $24K–$60K per month for a 3–6 person team including a lead data architect. Hire healthcare AI engineers and clinical data engineers.
For estimates, the healthcare AI cost calculator handles standard scopes.
Regulatory Reality for CRO AI
A CRO AI deployment touches regulated workflows. Three regulatory frames matter:
21 CFR Part 11. Any system that creates, modifies, maintains, or transmits electronic records used to satisfy a predicate FDA rule has to comply. Audit trails, electronic signatures, system validation documentation. See our 21 CFR Part 11 for AI page.
ICH GCP E6(R3). The 2025 revision elevated risk-based quality management. AI-driven risk-based monitoring fits cleanly into the R3 framework, but the system validation expectations are higher than R2.
EU GDPR for trials with EU sites. GDPR rules on processing health data for research are stricter than HIPAA in several places — particularly around consent and data subject rights for re-identifiable data. AI pipelines have to handle both regimes.
We do not provide regulatory affairs services directly. We build systems that pass sponsor and regulator review when paired with your existing QA, RA, and validation teams.
Frequently Asked Questions About Clinical Trial AI
The model reads the protocol’s inclusion and exclusion criteria, translates them into FHIR R4 resource queries (or OMOP CDM queries against a research warehouse), runs them across a target patient population, and produces a ranked match list with per-criterion confidence and rationale linking to the chart evidence. A human coordinator reviews the top matches before any patient contact.
In our engagements, AI screening produces 60–80% reduction in coordinator chart-review time versus manual screening, with sensitivity above 95% on inclusion criteria when the criteria are well-defined. Vague criteria (“clinically stable”) require human review regardless.
Yes. Synthetic control cohorts built from RWE datasets using propensity matching are common in oncology, rare disease, and pediatric trials where placebo arms are constrained. Defensibility to FDA depends on the RWE data quality and the matching methodology — we build for that defensibility.
Yes. 21 CFR Part 11 is the standard regulatory frame for any system creating or modifying electronic records used in FDA submissions. We build audit trails, electronic-signature support, and system validation documentation as part of Pilot-Ready Sprint work. See our 21 CFR Part 11 for AI page.
EHR data via FHIR R4 Bulk Data or HL7 v2, clinical data warehouses (Snowflake, Databricks, AWS HealthLake), OMOP CDM v5.4 research warehouses, ClinicalTrials.gov and AACT, MedDRA, WHODrug, SNOMED CT, LOINC, RxNorm, ICD-10-CM. De-identification under HIPAA Safe Harbor or Expert Determination is standard.
CRO AI platforms typically serve multiple sponsors simultaneously. We build with hard tenant isolation at the data layer, model layer, and audit-log layer. No sponsor sees another sponsor’s data, prompts, or outputs. Audit trails are sponsor-specific.
Yes. Every engagement begins with a BAA, and where EU-site data is in scope, also with GDPR Article 28 data processing agreements. BAA-eligible model providers only: OpenAI via Azure, Anthropic via Bedrock, Google Vertex AI, on-prem Llama/Mistral when sponsor contracts require fully air-gapped inference.